Skip to content
‹ Back to IndustriesSciences

How New Robotics are Shaping the Hospitals of Tomorrow

Photo courtesy of Alex Miller, U.S. ABB Media Relations Technology provider ABB announce on July 10 that it will install advanced collaborative robotics for medical labs and hospitals, beginning in Houston, Texas this October. The company announced in a press release that the global market is estimated to reach nearly 60,000 non-surgical medical robots by…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Healthcare · · AbbAutomationHealthcareHouston
Share
How New Robotics are Shaping the Hospitals of Tomorrow

Key takeaways

01

Photo courtesy of Alex Miller, U.S.

02

ABB Media Relations Technology provider ABB announce on July 10 that it will install advanced collaborative robotics for medical labs and hospitals, beginning in Houston, Texas this October.

03

The company announced in a press release that the global market is estimated to reach nearly 60,000 non-surgical medical robots by…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Photo courtesy of Alex Miller, U.S. ABB Media Relations

Technology provider ABB announce on July 10 that it will install advanced collaborative robotics for medical labs and hospitals, beginning in Houston, Texas this October.

The company announced in a press release that the global market is estimated to reach nearly 60,000 non-surgical medical robots by 2025, which would almost quadruple the total measured in 2018.

“The next-generation laboratory processes developed in Houston will speed manual medical laboratory processes, reducing and eliminating bottlenecks in laboratory work and enhancing safety and consistency. This is especially applicable for new high-tech treatments, such as the cancer therapies pioneered at the Texas Medical Center, which today require manual and time-consuming test processes,” ABB Robotics and Discrete Automation President Sami Atiya said in the statement.

The increase in automation will allow highly-skilled hospital workers to treat more patients and provide more personal attention, while robots conduct low value and repetitive tasks.

“With this exciting partnership, Texas Medical Center continues to push the boundaries of innovative collaboration with cutting-edge industry partners by establishing TMC as the epicenter for ABB Robotics’ entry into the healthcare space,” said Bill McKeon, President & CEO of Texas Medical Center in the press release. “Operating a city within a city that sees 10 million patients on an annual basis, it is essential to prioritize efficiency, and precision and to develop processes that are easily repeatable in nature. By bringing ABB into the fold at TMC Innovation with this first-of-its-kind R&D facility for creating robotics solutions in healthcare, TMC is emphasizing its commitment to doing just that.”

ABB has used collaborative robots in the food and beverage space in the past, and says the devices are well-suited for the medical environment. Activities the robots will be tasked with include dosing, mixing and pipetting, according to the statement.

For the latest healthcare news, head to our industry page!

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512